Dutch court blocks Merck's subcutaneous Keytruda sales across several European nations
A Dutch court ordered Merck to halt production and marketing of its subcutaneous Keytruda in multiple European countries after finding it infringed a Halozyme Therapeutics patent.
The Netherlands court determined that Merck violated a patent owned by Halozyme Therapeutics covering the subcutaneous formulation of the cancer drug Keytruda. Consequently, Merck must stop manufacturing and selling that version in France, Italy, Sweden, Switzerland and the Netherlands. The dispute centers on the best-selling treatment, but the existing intravenous formulation remains available to patients. Merck has been asked to comment on the ruling.
Why it matters
The injunction limits Merck's ability to offer a new Keytruda delivery method to European cancer patients, impacting treatment options and market dynamics.
In this story
